HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 282, Issue 20, 14845-14852, May 18, 2007

This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: 282/20/14845    most recent M606695200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Slack-Davis, J. K. Articles by Parsons, J. T. Search for Related Content PubMed PubMed Citation Articles by Slack-Davis, J. K. Articles by Parsons, J. T. Social Bookmarking                      What's this?

Cellular Characterization of a Novel Focal Adhesion Kinase Inhibitor^*

Jill K. Slack-Davis¹, Karen H. Martin¹, Robert W. Tilghman¹, Marcin Iwanicki, Ethan J. Ung, Christopher Autry, Michael J. Luzzio, Beth Cooper, John C. Kath, W. Gregory Roberts², and J. Thomas Parsons³

From the Department of Microbiology and Cancer Center, Health Sciences System, University of Virginia, Charlottesville, Virginia 22908 and Discovery Oncology, Pfizer Inc., Groton, Connecticut 06340

Focal adhesion kinase (FAK) is a member of a family of non-receptor protein-tyrosine kinases that regulates integrin and growth factor signaling pathways involved in cell migration, proliferation, and survival. FAK expression is increased in many cancers, including breast and prostate cancer. Here we describe perturbation of adhesion-mediated signaling with a FAK inhibitor, PF-573,228. In vitro, this compound inhibited purified recombinant catalytic fragment of FAK with an IC₅₀ of 4 nM. In cultured cells, PF-573,228 inhibited FAK phosphorylation on Tyr³⁹⁷ with an IC₅₀ of 30–100 nM. Treatment of cells with concentrations of PF-573,228 that significantly decreased FAK Tyr³⁹⁷ phosphorylation failed to inhibit cell growth or induce apoptosis. In contrast, treatment with PF-573,228 inhibited both chemotactic and haptotactic migration concomitant with the inhibition of focal adhesion turnover. These studies show that PF-573,228 serves as a useful tool to dissect the functions of FAK in integrin-dependent signaling pathways in normal and cancer cells and forms the basis for the generation of compounds amenable for preclinical and patient trials.

Received for publication, July 14, 2006 , and in revised form, March 13, 2007.

^* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. S1 and S2 and supplemental Movies S1 and S2.

¹ These authors contributed equally to this work.

² To whom correspondence should be addressed for all compound requests. ³To whom correspondence should be addressed: Dept. of Microbiology, University of Virginia, P.O. Box 800734, Jordan Hall, 1300 Jefferson Park Ave., Charlottesville, VA 22908-0734. Tel.: 434-924-5395; Fax: 434-982-1071; E-mail: jtp{at}virginia.edu.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				K. M. Bailey and J. Liu Caveolin-1 Up-regulation during Epithelial to Mesenchymal Transition Is Mediated by Focal Adhesion Kinase J. Biol. Chem., May 16, 2008; 283(20): 13714 - 13724. [Abstract] [Full Text] [PDF]

				S. M. Weis, S.-T. Lim, K. M. Lutu-Fuga, L. A. Barnes, X. L. Chen, J. R. Gothert, T.-L. Shen, J.-L. Guan, D. D. Schlaepfer, and D. A. Cheresh Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK J. Cell Biol., April 3, 2008; 181(1): 43 - 50. [Abstract] [Full Text] [PDF]

				W. G. Roberts, E. Ung, P. Whalen, B. Cooper, C. Hulford, C. Autry, D. Richter, E. Emerson, J. Lin, J. Kath, et al. Antitumor Activity and Pharmacology of a Selective Focal Adhesion Kinase Inhibitor, PF-562,271 Cancer Res., March 15, 2008; 68(6): 1935 - 1944. [Abstract] [Full Text] [PDF]

				J. T. Parsons, J. Slack-Davis, R. Tilghman, and W. G. Roberts Focal Adhesion Kinase: Targeting Adhesion Signaling Pathways for Therapeutic Intervention Clin. Cancer Res., February 1, 2008; 14(3): 627 - 632. [Abstract] [Full Text] [PDF]

				H. Lahlou, V. Sanguin-Gendreau, D. Zuo, Robert. D. Cardiff, G. W. McLean, M. C. Frame, and W. J. Muller Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression PNAS, December 18, 2007; 104(51): 20302 - 20307. [Abstract] [Full Text] [PDF]

				K. A. Owen, F. J. Pixley, K. S. Thomas, M. Vicente-Manzanares, B. J. Ray, A. F. Horwitz, J. T. Parsons, H. E. Beggs, E. R. Stanley, and A. H. Bouton Regulation of lamellipodial persistence, adhesion turnover, and motility in macrophages by focal adhesion kinase J. Cell Biol., December 17, 2007; 179(6): 1275 - 1287. [Abstract] [Full Text] [PDF]